ACCESSWIRE / October 27, 2014 / Firth Ratings helps push Juniper Networks, Inc. (NYSE: JNPR) shares 6.50% lower on Friday.
For an in-depth report on Juniper Networks, Inc. follow: www.pennystocktitans.com/stockquote/JNPR
Juniper Networks falls after failing to impress with earnings results and the company guided lower for 2015. Revenue in the three months ended in September fell 8% to $1.13 billion, yielding EPS of 36 cents. Analysts had expected $1.13 billion and 35 cents per share. For the current quarter, Juniper expects revenue in a range of $1.025 billion to $1.075 billion, and EPS of 28 cents to 32 cents. That compares to consensus of $1.17 billion and 40 cents per share.
Beating Q1 2015 earnings estimates helps Microsoft Corporation (NASDAQ: MSFT) shares move up 2.47% at Friday's close on about 61 million shares traded.
For an in-depth report on Microsoft Corporation follow: www.pennystocktitans.com/stockquote/MSFT
Microsoft beat analyst estimates for its Q1 2015 earnings. The company reported EPS of $0.68 and $23.201 billion in revenue (adjusted for one-time Nokia items). This is compared to the consensus of $0.56 EPS and $22.015 billion in revenue.
PennyStockTitans wants to help everyday people gain awareness about some of the hottest stocks trading in the stock market today. PennyStockTitans.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.pennystocktitans.com/ to get full access to our free stock reports.
Missing Q3 estimates pushes Southwestern Energy Co. (NYSE: SWN) shares down 4.84% on Friday.
For an in-depth report on Southwestern Energy Co. follow: www.pennystocktitans.com/stockquote/SWN
Southwestern Energy Co. reported third-quarter 2014 adjusted earnings of 50 cents per share. This missed the Zacks Consensus Estimate of 52 cents. The bottom line also dropped from the prior-year quarter's earnings of 51 cents. The company reported net income of $211 million in its third quarter.
Positive top-line data helps Cellceutix Corporation (OTC: CTIX) shares pop on Friday, closing up 5.96% and hitting a new 52-week high of $3.42.
For an in-depth report on Cellceutix Corporation follow: www.pennystocktitans.com/stockquote/CTIX
Cellcuetix Corporation announced positive top-line results for its Phase 2b randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections. Brilacidin is the first in a novel class of antibiotics known as defensin-mimetics being developed by Cellceutix.
Disclosure: PennyStockTitans.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
SOURCE: Stock Publisher